Biolegend, 505810, APC anti-mouse IFN-γ Antibody, 100μg

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: E. coli-expressed, recombinant mouse IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: ICFC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Red Laser (633 nm)
Application Notes: ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812). Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations. Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry. Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.
Application References(PubMed link indicates BioLegend citation): Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut) Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut) Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut) Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT) Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC) Ferrick D, et al. 1995. Nature 373:255. (FC) Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut) DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Montfort M, et al.2004. J. Immunol. 173:4084. PubMed Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC) Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations: Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed Chinta KC et al. 2018. Cell reports. 25(7):1938-1952 . PubMed Komuczki J, et al. 2019. Immunity. 50:1289. PubMed Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed Wang Z, et al. 2022. J Control Release. 349:929. PubMed Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed Shi X, et al. 2023. iScience. 26:106143. PubMed Tursi NJ, et al. 2023. Front Immunol. 14:1072810. PubMed Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed Latour YL, et al. 2023. Gut Microbes. 15:2192623. PubMed Mackin S, et al. 2023. Nat Microbiol. 8:569. PubMed Fu S, et al. 2023. Nat Commun. 14:2248. PubMed Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed Wang X, et al. 2023. Nat Commun. 14:3440. PubMed Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed Tian WJ, et al. 2021. Clin Exp Pharmacol Physiol. 48:902. PubMed Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed Li H, et al. 2022. Cancer Cell. 40:36. PubMed Stone ET, et al. 2022. Cell Rep. 38:110388. PubMed Guttman O, et al. 2022. J Cell Biol. 221: . PubMed Qu L, et al. 2022. Cell. 185:1728. PubMed Grebinoski S, et al. 2022. Nat Immunol. 23:868. PubMed Guo X, et al. 2022. Invest Ophthalmol Vis Sci. 63:12. PubMed Blanas A, et al. 2022. iScience. 25:104719. PubMed Gary EN, et al. 2022. Cell Rep Med. 3:100693. PubMed Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed Balood M, et al. 2022. Nature. 611:405. PubMed Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed Phares TW, et al. 2022. Front Pharmacol. 13:1029636. PubMed Xiao J, et al. 2023. J Clin Invest. 133: . PubMed Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed Cheng H, et al. 2023. Nat Metab. 5:314. PubMed Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed Vijver SV, et al. 2023. Front Immunol. 13:1100730. PubMed Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed Jiang L, et al. 2021. Nano Today. 36:. PubMed Tao X, et al. 2022. J Exp Med. 219:. PubMed McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed Du C, et al. 2016. Nat Commun. 7: 11120. PubMed Cella M, et al. 2019. Nat Immunol. 1.513888889. PubMed Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed Vacca M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed Yang N, et al. 2022. NPJ Vaccines. 7:120. PubMed Li X, et al. 2022. Nat Commun. 13:2794. PubMed Suresh R, et al. 2020. J Immunother Cancer. 8:. PubMed Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed Laroche-Lefebvre C, et al. 2016. J Immunol. 197: 3618 - 3627. PubMed Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed Yang C, et al. 2018. J Immunol. 200:1316. PubMed Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed Angiari S, et al. 2020. Cell Metab. 31:391. PubMed Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed Turner JA, et al. 2020. Immunity. 53:1202. PubMed Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed Oda SK, et al. 2020. J Exp Med. 217: . PubMed Devalaraja S, et al. 2020. Cell. 1098:180. PubMed Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed Zhao Y, et al. 2015. PLoS One. 10: 0134797. PubMed Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed Li Y, et al. 2020. Cell Rep. 30:1753. PubMed Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed Lu J, et al. 2018. ACS Nano. 12:11041. PubMed Diao L, et al. 2022. iScience. 25:105511. PubMed Guo Q, et al. 2021. Front Cardiovasc Med. 8:633212. PubMed Gu M, et al. 2021. Nat Immunol. 22:193. PubMed Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed Rao E, et al. 2021. Sci Immunol. 6:. PubMed Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed Qi X, et al. 2019. Nat Commun. 10:2141. PubMed Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed Saini V, et al. 2020. Nat Commun. 0.845138889. PubMed Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed Konrath KM, et al. 2022. Cell Rep. 38:110318. PubMed Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed Cao W, et al. 2017. Immunity. 47:1182. PubMed Wang C, et al. 2021. Cell Rep. 37:110021. PubMed Suah AN, et al. 2021. J Clin Invest. 131:. PubMed Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed Gary EN, et al. 2021. iScience. 24(7):102699. PubMed Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed Lai C, et al. 2009. Invest Ophthalmol Vis Sci. 50:4279. PubMed Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed Yang K, et al. 2022. J Clin Invest. 132:. PubMed Mills C, et al. 2022. Cells. 11:. PubMed Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed Wang B, et al. 2022. Nat Commun. 13:3821. PubMed Li H, et al. 2022. Theranostics. 12:6422. PubMed Marks KE, et al. 2021. Cell Reports. 35(13):109303. PubMed Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed Harty J 2009. Infect Immun. 77:1894. PubMed Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed Deng Z, et al. 2017. Oncogene. 36:639. PubMed Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed Yang S, et al. 2019. Nat Commun. 10:2782. PubMed Snell LM, et al. 2018. Immunity. 49:678. PubMed Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed Wu L, et al. 2022. Theranostics. 12:842. PubMed Bhattacharya D, et al. 2014. J Biol Chem. 289:16508. PubMed El-Zaatari M, et al. 2014. J Immunol. 193:807. PubMed Souza COS, et al. 2021. iScience. 24(6):102548. PubMed Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed Kim C, et al. 2019. Cell Rep. 29:2202. PubMed Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed Shi R, et al. 2022. Theranostics. 12:875. PubMed Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed Baban B, et al. 2021. JCI Insight. 6:00. PubMed Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed Qi S et al. 2016. eLife. 5 pii: e14756. PubMed van Montfoort N, et al. 2018. Cell. 175:1744. PubMed Park JY, et al. 2019. Cell Rep. 27:2548. PubMed Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed Yong L, et al. 2022. Nat Commun. 13:4255. PubMed Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed Yuan Y, et al. 2022. Cell Rep. 38:110256. PubMed Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed Reinfeld BI, et al. 2021. Nature. 593:282. PubMed Lu X, et al. 2015. J Immunol. 194:2011. PubMed Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed Huang F, et al. 2018. Oncoimmunology. 7:e1450713. PubMed Levesque S, et al. 2019. Oncoimmunology. 8:e1657375. PubMed Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed Li YN, et al. 2022. Nat Commun. 13:4074. PubMed Yang B, et al. 2022. Bioengineered. 13:2685. PubMed Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed Chou T, et al. 2016. Nat Commun. 7:11904. PubMed Murakami R, et al. 2013. PLoS One. 8:73270. PubMed Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed Daneshmandi S, et al. 2021. Elife. 10:. PubMed Dai R, et al. 2021. Front Immunol. 12:727046. PubMed Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed Ma X, et al. 2020. Immunity. 53:1315. PubMed Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed Montfort M, et al. 2004. J Immunol. 173:4084. PubMed Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed Pandit M, et al. 2021. Eur J Immunol. 51:1461. PubMed Zeng Q, et al. 2022. iScience. 25:105151. PubMed Derada Troletti C, et al. 2021. Cell Reports. 35(9):109201. PubMed Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed Jin R, et al. 2008. J Immunol. 180:2256. PubMed Muri J, et al. 2020. eLife. 9:e53627.. PubMed Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed Gupta S, et al. 2022. Life Sci. 288:120182. PubMed Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed M H, et al. 2016. Open Bio. 6: 150208. PubMed Moon J, et al. 2020. Immune Netw. 20:e40. PubMed Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed Kang YH, et al. 2019. Nat Commun. 10:912. PubMed Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed Li E, et al. 2021. Front Immunol. 12:667177. PubMed Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed Kurihara T, et al. 2015. PLoS One. 10: e0139692. PubMed Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed Lee J, et al. 2007. Nat Immunol. 8:181. PubMed Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed Byrne K, et al. 2014. J Immunol. 192:1433. PubMed Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed Okuyama Y, et al. 2020. FASEB J. 540:34. PubMed Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed Sun Y, et al. 2020. J Immunol. 205:2649. PubMed Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed Wagner AK, et al. 2022. iScience. 25:105137. PubMed Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed Sheng J, et al. 2021. eLife. 10:00. PubMed Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed Bransi A, et al. 2015. Cancer Immunol Res. 3: 1279 - 1288. PubMed Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed Kwak JE, et al. 2019. Nat Commun. 10:3836. PubMed Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed Yang N, et al. 2021. NPJ Precis Oncol. 5:37. PubMed Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed Wang F, et al. 2021. Neoplasia. 23:281. PubMed Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed Yang L, et al. 2021. Front Immunol. 12:722273. PubMed Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed Tang L, et al. 2022. Front Immunol. 12:770402. PubMed Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed Kalim KW, et al. 2021. Front Immunol. 12:726393. PubMed Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
RRID: AB_315403 (BioLegend Cat. No. 505809) AB_315404 (BioLegend Cat. No. 505810)
Structure: Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources: CD8+ and CD4+ T cells, NK cells
Cell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type: Tregs
Biology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID: 15978
UniProt: View information about IFN-gamma on UniProt.org
Clone: XMG1.2
Regulatory Status: RUO
Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype: Rat IgG1, κ